ARCHIFAR Powder for solution for injection / infusion Ref.[28180] Active ingredients: Meropenem

Source: Υπουργείο Υγείας (CY)  Revision Year: 2020  Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

4.1. Therapeutic indications

Meropenem is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1):

  • Severe pneumonia, including hospital and ventilator-associated pneumonia.
  • Broncho-pulmonary infections in cystic fibrosis.
  • Complicated urinary tract infections.
  • Complicated intra-abdominal infections.
  • Intra- and post-partum infections.
  • Complicated skin and soft tissue infections.
  • Acute bacterial meningitis.

Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2. Posology and method of administration

Posology

The tables below provide general recommendations for dosing.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.

Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).

Adults and adolescents:

InfectionDose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia500 mg or 1 g
Broncho-pulmonary infections in cystic fibrosis2 g
Complicated urinary tract infections500 mg or 1 g
Complicated intra-abdominal infections500 mg or 1 g
Intra- and post-partum infections500 mg or 1 g
Complicated skin and soft tissue infections500 mg or 1 g
Acute bacterial meningitis2 g
Management of febrile neutropenic patients1 g

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see section 6.2, 6.3 and 6.6).

Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.

Renal impairment

The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.

Creatinine clearance (ml/min) Dose (based on “unit” dose range of 500 mg or 1g or 2g, see table above) Frequency
26-50one unit doseevery 12 hours
10-25half of one unit doseevery 12 hours
<10half of one unit doseevery 24 hours

Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.

There are no established dose recommendations for patients receiving peritoneal dialysis.

Hepatic impairment

No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).

Dose in elderly patients

No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.

Paediatric population

Children under 3 months of age

The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).

Children from 3 months to 11 years of age and up to 50 kg body weight

The recommended dose regimens are shown in the table below:

InfectionDose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia10 or 20 mg/kg
Broncho-pulmonary infections in cystic fibrosis40 mg/kg
Complicated urinary tract infections10 or 20 mg/kg
Complicated intra-abdominal infections10 or 20 mg/kg
Complicated skin and soft tissue infections10 or 20 mg/kg
Acute bacterial meningitis40 mg/kg
Management of febrile neutropenic patients20 mg/kg

Children over 50 kg body weight

The adult dose should be administered.

There is no experience in children with renal impairment.

Method of administration

Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.

4.9. Overdose

Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.

In individuals with normal renal function, rapid renal elimination will occur.

Haemodialysis will remove meropenem and its metabolite.

6.3. Shelf life

36 months.

Intravenous bolus injection administration

A solution for bolus injection is prepared by dissolving the medicinal product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C).

From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.

If not used immediately in-use storage times and conditions are the responsibility of the user.

Intravenous infusion administration

A solution for infusion is prepared by dissolving the medicinal product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C or 24 hours under refrigerated conditions (2-8°C).

From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.

If not used immediately in-use storage times and conditions are the responsibility of the user.

Reconstituted solution of the product in 5% dextrose solution should be used immediately.

The constituted solutions should not be frozen.

6.4. Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5. Nature and contents of container

Type I clear glass vials of 20ml and 30ml. Packs of 1, 10, 25, 50 and 100 vials are available.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Standard aseptic technique should be employed during constitution. Shake constituted solution before use.

All vials are for single use only.

It is recommended to use freshly prepared solutions.

Injection: Meropenem to be used for bolus intravenous injection should be constituted with sterile water for injection.

Infusion: For intravenous infusion meropenem may be directly constituted with 0.9% sodium chloride or 5% glucose solution for infusion.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.